Hyperinsulinism‐induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)‐rywn chemotherapy in a pediatric AML patient
Authors:
- 6 February 2024
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (4) , e30914
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 StudyBlood, 2023
- 2023 ASPHO Conference Paper and Poster IndexPediatric Blood & Cancer, 2023
- Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaFrontiers in Pediatrics, 2022
- Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001Journal of Clinical Oncology, 2021
- L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of OdishaIndian Journal of Pharmacology, 2016
- L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient reportJournal of Pediatric Endocrinology and Metabolism, 2015
- Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case reportExperimental Hematology & Oncology, 2012